Innate Pharma Sa Share Price Today
(NASDAQ: IPHA)

Name: Innate Pharma Sa Share Price Today (NASDAQ: IPHA) - Innate Pharma Sa Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Innate Pharma Sa share price is $2.11 & ₹183.50 as on 6 Mar 2025, 2.30 'hrs' IST

$2.11

▲

0.12

(6.03%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Innate Pharma Sa share price in Dollar and Rupees. Guide to invest in Innate Pharma Sa stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Innate Pharma Sa, along with analyst recommendations, forecasts, and comprehensive financials.

Innate Pharma Sa share price movements

Today's Low: $2.04
Today's High: $2.15
$2.11
3.32%
Downside
Day's Volatility :5.12%
Upside
1.86%
52 Weeks Low: $1.29
52 Weeks High: $3.51
$2.11
38.86%
Downside
52 Weeks Volatility :63.26%
Upside
39.9%

Innate Pharma Sa (IPHA) Returns

Period	Innate Pharma Sa	Index (Russel 2000)
3 Months	37.24%	0.0%
6 Months	-13.85%	0.0%
1 Year	-23.9%	0.0%
3 Years	-26.43%	-11.6%

Innate Pharma Sa (IPHA) Key Statistics

in dollars & INR

Previous Close	$1.99
Open	$2.15
Today's High	$2.15
Today's Low	$2.04
Market Capitalization	$191.1M
Today's Volume	$5.0K
52 Week High	$3.5107
52 Week Low	$1.29
Revenue TTM	$33.8M
EBITDA	$-36.0M
Earnings Per Share (EPS)	$-0.43
Profit Margin	-100.78%
Quarterly Earnings Growth YOY	-0.75%
Return On Equity TTM	-78.59%

How to invest in Innate Pharma Sa Stock (IPHA) from India?

It is very easy for Indian residents to invest directly in Innate Pharma Sa from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Innate Pharma Sa stock in both Indian Rupees (INR) and US Dollars (USD). Search for Innate Pharma Sa or IPHA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Innate Pharma Sa or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Innate Pharma Sa shares which would translate to 0.412 fractional shares of Innate Pharma Sa as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Innate Pharma Sa, in just a few clicks!

Returns in Innate Pharma Sa (IPHA) for Indian investors in Rupees

The Innate Pharma Sa stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Innate Pharma Sa investment value today

Current value as on today

₹85,497

Returns

₹14,503

(-14.5%)

Returns from Innate Pharma Sa Stock

₹19,466 (-19.47%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Innate Pharma Sa (IPHA)

-18%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Innate Pharma Sa Stock from India on INDmoney has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Innate Pharma Sa

Exchange Traded Concepts, LLC
0.09%
Morgan Stanley - Brokerage Accounts
0.05%
Citadel Advisors Llc
0.01%

Analyst Recommendation on Innate Pharma Sa

Buy

70%Buy

30%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Innate Pharma Sa(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Innate Pharma Sa Stock (IPHA)

What analysts predicted

Upside of 279.86%

Target:

$8.02

Current:

$2.11

Insights on Innate Pharma Sa Stock (Ticker Symbol: IPHA)

Price Movement
In the last 3 months, IPHA stock has moved up by 37.2%
Increasing Revenue
Revenue is up for the last 2 quarters, 6.17M → 12.34M (in $), with an average increase of 50.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 5 quarters, 1.71M → -24.76M (in $), with an average decrease of 150.9% per quarter
IPHA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 84.9%
IPHA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 77.4%
Price to Sales
ForIPHA every $1 of sales, investors are willing to pay $4.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

IPHA Innate Pharma Sa Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$90.9M	↑ 144.83%
Net Income	$3.5M	↓ 106.3%
Net Profit Margin	3.82%	↑ 152.1%

	FY19	Y/Y Change
Revenue	$76.6M	↓ 13.67%
Net Income	$-23.3M	↓ 787.6%
Net Profit Margin	-30.4%	↓ 34.22%

	FY20	Y/Y Change
Revenue	$84.9M	↑ 1.16%
Net Income	$-77.8M	↑ 205.19%
Net Profit Margin	-91.7%	↓ 61.3%

	FY21	Y/Y Change
Revenue	$13.7M	↓ 82.64%
Net Income	$-66.9M	↓ 7.58%
Net Profit Margin	-488.24%	↓ 396.54%

	FY22	Y/Y Change
Revenue	$52.5M	↑ 309.83%
Net Income	$-104.9M	↑ 67.58%
Net Profit Margin	-199.65%	↑ 288.59%

	FY23	Y/Y Change
Revenue	$56.6M	↑ 4.56%
Net Income	$-8.3M	↓ 92.36%
Net Profit Margin	-14.59%	↑ 185.06%

	Q1 FY23	Q/Q Change
Revenue	$21.5M	↑ 141.89%
Net Income	$919.4K	↓ 101.33%
Net Profit Margin	4.27%	↑ 779.41%

	Q2 FY23	Q/Q Change
Revenue	$38.3M	↑ 75.85%
Net Income	$1.9M	↑ 100.0%
Net Profit Margin	4.86%	↑ 0.59%

	Q3 FY23	Q/Q Change
Revenue	$10.7M	↓ 69.67%
Net Income	$-4.6M	↓ 370.31%
Net Profit Margin	-43.31%	↓ 48.17%

	Q4 FY23	Q/Q Change
Revenue	$21.4M	↑ 100.0%
Net Income	$-9.3M	↑ 100.0%
Net Profit Margin	-43.31%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$6.2M	↓ 71.21%
Net Income	$-12.4M	↑ 33.31%
Net Profit Margin	-200.6%	↓ 157.29%

	Q2 FY24	Q/Q Change
Revenue	$12.3M	↑ 100.0%
Net Income	$-24.8M	↑ 100.0%
Net Profit Margin	-200.6%	↑ 0.0%

	FY18	Y/Y Change
Profit	$90.9M	↑ 144.83%

	FY19	Y/Y Change
Profit	$26.5M	↓ 70.19%

	FY20	Y/Y Change
Profit	$24.4M	↓ 15.75%

	FY21	Y/Y Change
Profit	$-39.4M	↓ 273.89%

	FY22	Y/Y Change
Profit	$-2.1M	↓ 94.2%

	FY23	Y/Y Change
Profit	$-4.5M	↑ 103.61%

	Q1 FY23	Q/Q Change
Profit	$4.7M	↓ 186.68%

	Q2 FY23	Q/Q Change
Profit	$21.3M	↑ 348.66%

	Q3 FY23	Q/Q Change
Profit	$-1.6M	↓ 107.97%

	Q4 FY23	Q/Q Change
Profit	$-3.1M	↑ 100.0%

	Q1 FY24	Q/Q Change
Profit	$-8.4M	↑ 167.61%

	Q2 FY24	Q/Q Change
Profit	$-16.7M	↑ 100.0%

	FY18	Y/Y Change
Operating Cash Flow	$-37.0M	↓ 32.31%
Investing Cash Flow	$27.6M	↓ 182.41%
Financing Cash Flow	$69.6M	↑ 6590.93%

	FY19	Y/Y Change
Operating Cash Flow	$38.8M	↓ 207.36%
Investing Cash Flow	$-69.0M	↓ 355.86%
Financing Cash Flow	$86.4M	↑ 27.02%

	FY20	Y/Y Change
Operating Cash Flow	$-63.0M	↓ 248.34%
Investing Cash Flow	$-16.3M	↓ 78.48%
Financing Cash Flow	$-1.4M	↓ 101.46%

	FY21	Y/Y Change
Operating Cash Flow	$-66.1M	↑ 12.84%
Investing Cash Flow	$-1.0M	↓ 93.14%
Financing Cash Flow	$30.3M	↓ 2460.74%

	FY22	Y/Y Change
Operating Cash Flow	$-20.3M	↓ 67.23%
Investing Cash Flow	$2.0M	↓ 304.69%
Financing Cash Flow	$-1.9M	↓ 106.82%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-21.6M	↑ 0.0%
Investing Cash Flow	$-131.6K	↓ 110.83%
Financing Cash Flow	$-1.1M	↑ 0.0%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-12.4M	↓ 43.25%
Investing Cash Flow	$-133.4K	↑ 0.0%
Financing Cash Flow	$-1.4M	↑ 17.33%

Innate Pharma Sa Technicals Summary

Sell

Neutral

Buy

Innate Pharma Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Innate Pharma Sa (IPHA) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Innate Pharma Sa	2.05%	-13.85%	-23.9%	-26.43%	-69.21%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Innate Pharma Sa	NA	NA	NA	0.0	-0.79	-0.14	NA	0.36
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Innate Pharma Sa	Buy	$191.1M	-69.21%	NA	-100.78%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Innate Pharma Sa

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Organization	Innate Pharma Sa
Employees	168
CEO	Mr. Jonathan E. Dickinson
Industry	Health Technology

Management People of Innate Pharma Sa

Name	Title
Mr. Yannis Morel Ph.D.	Executive VP, COO & Member of Executive Board
Mr. Jonathan E. Dickinson	Chairman of the Executive Board & CEO
Dr. François Romagné Ph.D.	Founder
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.	Founder, Senior VP & Chief Scientific Officer
Dr. Marc Bonneville Ph.D.	Founder
Mr. Jean Jacques Fournié Ph.D.	Founder
Mr. Alessandro Moretta M.D., Ph.D.	Founder
Mr. Frederic Lombard M.B.A.	Senior VP & CFO
Dr. Sonia Quaratino M.D., Ph.D.	Executive VP, Chief Medical Officer & Member of Executive Board
Mr. Arvind Sood	Executive VP, President of US Operations & Member of Executive Board

Important FAQs about investing in IPHA Stock from India :

What is Innate Pharma Sa share price today?

Innate Pharma Sa share price today stands at $2.11, Open: $2.15 ; Previous Close: $1.99 ; High: $2.15 ; Low: $2.04 ; 52 Week High: $3.51 ; 52 Week Low: $1.29.

The stock opens at $2.15, after a previous close of $1.99. The stock reached a daily high of $2.15 and a low of $2.04, with a 52-week high of $3.51 and a 52-week low of $1.29.

Can Indians buy Innate Pharma Sa shares?

Yes, Indians can invest in the Innate Pharma Sa (IPHA) from India.

With INDmoney, you can buy Innate Pharma Sa at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Innate Pharma Sa at zero transaction cost.

How can I buy Innate Pharma Sa shares from India?

It is very easy to buy Innate Pharma Sa from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Innate Pharma Sa (IPHA) be purchased?

Yes, you can buy fractional shares of Innate Pharma Sa with INDmoney app.

What are the documents required to start investing in Innate Pharma Sa stocks?

To start investing in Innate Pharma Sa, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.